diabetestalk.net

Fruits Diabetics Should Avoid

Share on facebook

Amazing Benefits Of Mangoes For Diabetes

Just the thought of mangeos may elicit images of tropical beaches, palm trees, ocean waves gently covering the sandy beach…eating mangeos by the ocean with cool ocean breezes wafting over you… Mangos are the fruit of the mango tree—and it brings images of a tropical island because it is a tropical fruit. Mangos are actually the world’s most popular fruit! Mangos are full of vitamins—particularly Vitamins A and C—where one mango provides about 1/3 of the RDA for Vitamin A and nearly 100% of the RDA for Vitamin C. Mangos also contain significant amounts of Vitamins E, K and B complex vitamins (except for Vitamin B12). Mangos are also high in fiber and contain calcium, potassium and copper. They also contain some omega-3 and omega-6 fatty acids, though overall, are very low in fat. One ripe mango can contain 31 grams of sugar, but its glycemic load is only 10—the fiber in mango helps limit the rapid absorption of the sugars. One mango also has 135 calories—not so bad![1] Mangos are higher in sugars than many other fruits, but that doesn’t mean you shouldn’t eat mangeos. The Mayo clinic recommends that one serving of fruit should contain 15 grams of carbohydrate—t Continue reading >>

Share on facebook

Popular Questions

  1. CalgaryDiabetic

    Metformin (very) bad if this is true

    http://www.medscape.com/viewarticle/877965

  2. CalgaryDiabetic

    Metformin Use Linked to Increased Dementia, Parkinson's Risk in Patients With Diabetes
    Deborah Brauser
    March 30, 2017
    VIENNA, Austria — Long-term use of the diabetes medication metformin may increase the risk for neurodegenerative disease in patients with type 2 diabetes mellitus (T2DM), new research suggests.
    In a cohort study that followed about 9300 patients with T2DM in Taiwan for up to 12 years, the risk for Parkinson's disease (PD) or Alzheimer's dementia was more than double during a 12-year period for those who took metformin vs those who did not — even after adjusting for multiple confounders.
    In addition, outcome risks increased progressively with higher dosage and longer duration of treatment.
    The results were presented here at AD/PD 2017: The 13th International Conference on Alzheimer's and Parkinson's Diseases by Yi-Chun Kuan, MD, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.


    Dr Yi-Chun Kuan Interestingly,
    recent research has suggested that use of metformin may protect against neurodegenerative diseases. When asked about that, Dr Kuan told Medscape Medical News that "some studies have actually found positive [outcomes] but some have been negative." So the researchers wanted to look into this using their own data.
    "We'd heard about a possible protective effect from metformin. However, we found the reverse," she said, but stressed that large-scale, prospective studies in other countries are needed to clarify the results.
    Higher Cumulative Incidences
    The investigators note that past research has shown a link between T2DM and increased risk for neurodegenerative diseases, but there's been "some question" about the association with specific diabetes medications.
    They examined records for patients with T2DM from the National Health Insurance research database of Taiwan, including 4651 who had metformin prescriptions and 4651 matched controls who were not using the medication.
    After adjustment for factors such as age, sex, and diabetes severity, "the cumulative incidences of Parkinson's and dementia were significantly higher for our metformin cohort" at 12 years (P < .001), reported Dr Kuan.

  3. CalgaryDiabetic

    Table 1. Outcomes in Metformin Users vs Nonusers


    Outcome
    Event Rate (%)
    Adjusted Hazard Ratio (95% Confidence Interval)
    PD
    6.85 vs 2.78
    2.27 (1.66 - 3.07)
    All-cause dementia
    11.5 vs 6.7
    1.66 (1.35 - 2.04)
    Alzheimer's dementia
    1.64 vs 0.83
    2.13 (1.20 - 3.79)
    Vascular dementia
    1.64 vs 0.69
    2.30 (1.25 - 4.22) In addition, the outcomes mostly increased as the use duration and dosage of metformin increased, especially with use for more than 300 days and doses greater than 240 g.
    Table 2. Comparison of Metformin Use Duration vs Nonuse


    Risk
    Event Rate (%)
    Adjusted Hazard Ratio (95% Confidence Interval)
    For PD
    <180 d
    5.90
    1.77 (1.17 - 2.68)
    180 - 300 d
    4.30
    1.46 (0.90 - 2.37)
    300 - 400 d
    6.05
    2.20 (1.47 - 3.28)
    ≥400 d
    14.3
    4.49 (3.06 - 6.58)
    For all-cause dementia
    <180 d
    7.99
    1.02 (0.74 - 1.41)
    180 - 300 d
    11.4
    1.79 (1.32 - 2.43)
    300 - 400 d
    10.4
    1.61 (1.21 - 2.16)
    ≥400 d
    20.6
    2.84 (2.12 - 3.82) Continue Reading

  4. -> Continue reading
read more close

Related Articles

Popular Articles

More in diabetes